IPSEN (OTCMKTS:IPSEY) Reaches New 1-Year High – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares hit a new 52-week high on Thursday . The company traded as high as $39.10 and last traded at $39.10, with a volume of 610 shares trading hands. The stock had previously closed at $37.57.

Analyst Ratings Changes

Several brokerages have issued reports on IPSEY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. UBS Group downgraded IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 8th. Finally, BNP Paribas lowered IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, IPSEN has a consensus rating of “Hold”.

IPSEN Trading Up 4.1%

The stock has a fifty day moving average of $36.10 and a 200-day moving average of $34.07.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).